MAXIND

Max India Share Price

 

Stock Result Declared

 

Start SIP in MAXIND

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume

Investment Returns

  • Over 1 Month -1.44%
  • Over 3 Month + 0.22%
  • Over 6 Month + 5.59%
  • Over 1 Year -10.57%

Smart Investing Starts Here Start SIP with Max India for Steady Growth!

Invest Now

Max India Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Max India Financials

Max India Technicals

EMA & SMA

Current Price
₹207.57
-3.35 (-1.59%)
pointer
  • Bearish Moving Average 14
  • Bullish Moving Average 2
  • 20 Day
  • ₹211.16
  • 50 Day
  • ₹211.49
  • 100 Day
  • ₹209.30
  • 200 Day
  • ₹209.95

Resistance and Support

207.86 Pivot Speed
  • R3 219.69
  • R2 215.84
  • R1 211.71
  • S1 203.73
  • S2 199.88
  • S3 195.75

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Max India focuses on healthcare and senior living services, providing high-quality healthcare solutions through its network of hospitals and senior care facilities. It aims to enhance well-being and quality of life for individuals across India.

Max India has an operating revenue of Rs. 155.70 Cr. on a trailing 12-month basis. An annual revenue de-growth of -16% needs improvement, Pre-tax margin of -96% needs improvement, ROE of -39% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -10% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 14 which is a POOR score indicating inconsistency in earnings, a RS Rating of 57 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 41 indicates it belongs to a fair industry group of Medical-Hospitals and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Max India Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-13 Quarterly Results
2025-08-05 Quarterly Results & Others Inter-alia, to consider 1. Potential Fund Raising through permissible modes and to consider ancillary actions for aforesaid fund raising subject to the necessary regulatory & statutory approvals issue of equity shares of Rs. 10/- in the ratio of 19:100 @ premium of Rs. 140/-.
2025-05-30 Audited Results
2025-04-15 Others Inter-alia, to consider 1. Proposal of Fund raising by way of equity shares or other securities of the Company through a rights issue and/or any other permissible mode. issue of equity shares of Rs. 10/- in the ratio of 19:100 @ premium of Rs. 140/-.
2025-02-06 Quarterly Results & Fund Raising

Max India F&O

Max India Shareholding Pattern

49.58%
0%
7.02%
0%
35.06%
8.34%

Max India FAQs

Max India share price is ₹207 As on 14 November, 2025 | 20:57

The Market Cap of Max India is ₹1088.3 Cr As on 14 November, 2025 | 20:57

The P/E ratio of Max India is -7.2 As on 14 November, 2025 | 20:57

The PB ratio of Max India is 1.9 As on 14 November, 2025 | 20:57

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23